Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Tarsus (NASDAQ: TARS) will report third quarter 2025 financial results on Tuesday, November 4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus (NASDAQ: TARS) will report third quarter 2025 financial results on Tuesday, November 4, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET to present results and a corporate update.
Participants may access the live webcast online; a recorded version will be posted on the company website shortly after the call and archived for approximately 90 days.
Details
News Market Reaction – TARS
On Oct 29, the first trading day after this news, TARS closed 0.06% below the previous close.
Data tracked by StockTitan Argus for the Oct 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
| Media Contact: |
| Adrienne Kemp |
| Sr. Director, Corporate Communications |
| (949) 922-0801 |
| AKemp@tarsusrx.com |
| Investor Contact: |
| David Nakasone |
| Head of Investor Relations |
| (949) 620-3223 |
| DNakasone@tarsusrx.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.